Alzheimer’s Disease Neuroimaging Initiative (ADNI)  
DATA USE AGREEMENT

I request access to data collected by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) for the purpose of scientific investigation, teaching or the planning of clinical research studies and agree to the following terms.

1. I will receive access to de-identified data and will not attempt to establish the identity of, or attempt to contact any of the ADNI subjects.

2. I will not attempt to make direct contact with ADNI PIs or staff at sites concerning the specific results of individual subjects.

3. I will not further disclose these data beyond the uses outlined in this agreement and my data use application and understand that redistribution of data in any manner is prohibited.

4. I will require anyone on my team who utilizes these data, or anyone with whom I share these data to comply with this data use agreement.

5. I will accurately provide the requested information for persons who will use these data and the analyses that are planned using these data.

6. I will respond promptly and accurately to annual requests to update this information.

7. I will comply with any rules and regulations imposed by my institution and its institutional review board in requesting these data.

If I publish abstracts using data from ADNI, I agree to the following:

8. I will cite ADNI as the source of data and the ADNI funding sources in the abstract as space allows.

9. Acknowledgement of ADNI will not be cited in the authorship line of the abstract.

If I publish manuscripts using data from ADNI, I agree to the following:

10. On the by-line of the manuscript, after the named authors, I will include the phrase “for the Alzheimer’s Disease Neuroimaging Initiative*” with the asterisk referring to the following statement and list of names:

   *Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at:  

11. I will include language similar to the following in the methods section of my manuscripts.
in order to accurately acknowledge data gathering by the ADNI personnel. Depending
upon the length and focus of the article, it may be appropriate to include more or less
than the example below, however inclusion of some variation of the language shown
below is mandatory.

Data used in the preparation of this article were obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in
2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner,
MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging
(MRI), positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of mild
cognitive impairment (MCI) and early Alzheimer’s disease (AD). For up-to-date information,
see www.adni-info.org.

12. I will acknowledge funding by the ADNI in the support acknowledgement section of the
manuscript using language similar to the following:

Data collection and sharing for this project was funded by the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and
DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded
by the National Institute on Aging, the National Institute of Biomedical Imaging and
Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s
Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.;
Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan
Pharmaceuticals, Inc.; Eli Lilly and Company; Euroimmun; F. Hoffmann-La Roche Ltd and
its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen
Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson
Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;
Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis
Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical
Company; and Transition Therapeutics. The Canadian Institutes of Health Research is
providing funds to support ADNI clinical sites in Canada. Private sector contributions are
facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee
organization is the Northern California Institute for Research and Education, and the study is
coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern
California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the
University of Southern California.

13. I will submit all manuscripts to the ADNI Data and Publications Committee (DPC) prior to
submitting to a journal. This review will not be a scientific review, but is intended to
ensure that items 7-12 above are correctly implemented. The DPC will maintain
confidentiality of the manuscript and will complete its review within 2 weeks.

14. I will ensure that Investigators who utilize ADNI data use appropriate administrative,
physical and technical safeguards to prevent use or disclosure of the data other than as
provided for by this Agreement.

15. I will report any use or disclosure of the data not provided for by this Agreement of which
I become aware within 15 days of becoming aware of such use or disclosure.
IMPORTANT NOTE: It is the policy of the Alzheimer’s Disease Neuroimaging Initiative to make analyzed data available to investigators as quickly as possible. However, data analysis for this project is expected to take years as methods for analysis of these datasets evolve. Therefore, I understand that any processed data that I download might be preliminary and that results may change as new methods of analysis are implemented. I will familiarize myself with the analysis methods so that I am aware of the limitations of these data prior to using them for scientific purposes.

Finally, because “preliminary data” will be posted on the database, in the event that I download data from the ADNI database for the purposes of analysis and future publication in the form of abstracts and/or publications, I will note the version of the data I download, and I will check the database to determine if updated data has been provided prior to submission of any material for publication.

I understand that failure to abide by these guidelines will result in termination of my privileges to access ADNI data.

Electronic Signature of User